Apelvis: a new option for precision targeted therapy, a non-traditional chemotherapy drug

Alpelisib (Alpelisib) is not a chemotherapy drug in the traditional sense. Chemotherapy drugs typically work by affecting a wide range of rapidly dividing cells in the body, including malignant tumor cells as well as some normal, healthy cells. Because of this, chemotherapy drugs are often accompanied by a series of serious side effects. In contrast, Apelvis is a new type of kinase inhibitor that uses a more precise targeted therapy. These drugs can specifically attack certain types of cancer cells while reducing damage to normal cells.

Patients will need detailed genetic testing before taking Apelvis. This is because Apelvis is only effective in breast cancer patients with a specific genetic profile, namely those with hormone receptor (HR)-positive, HER2-negative, and PIK3CA mutations. PIK3CA mutations can lead to abnormal activation of the PI3K pathway in cells, thereby driving the unlimited proliferation and division of cancer cells.

Unlike chemotherapy drugs, Apelvis does not directly interfere with the normal reproduction of cells andDNA replication process. Instead, it specifically targets and inhibits the abnormally activated PI3K pathway in cancer cells. By precisely blocking this pathway, Apelvis can effectively inhibit the growth and spread of cancer cells while reducing damage to normal cells.

However, in some cases, doctors may consider combining Apelvis with other chemotherapy drugs in the hope of achieving better results. This combination treatment plan is formulated based on the patient's specific condition and physical condition and is designed to maximize treatment effectiveness and reduce the occurrence of side effects. As a new type of targeted therapy drug, Apelvis provides more treatment options for breast cancer patients.